Innovation and sustainability in immune-mediated diseases: An Italian multidisciplinary consensus across gastroenterology, dermatology, and rheumatology.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Scaldaferri Franco, Di Vincenzo Federica, Falco Gennaro Marco, Lazzaro Federico Giuseppe, Aloi Marina, Alivernini Stefano, Scolieri Palma, Balestrieri Paola, Basile Michele, Cela Eneida, Bianchi Luca, Biancone Livia, Bosello Silvia Laura, Calabrese Emma, Caldarola Giacomo, Cammarota Giovanni, Capacci Annunziata, Chimenti Maria Sole, Cicala Michele, Cicchetti Americo, Conti Fabrizio, Corsano Barbara, Dattola Annunziata, De Angelis Paola, De Simone Clara, Picchianti-Diamanti Andrea, Di Brino Eugenio, Gori Niccolò, Faggiani Roberto, Festa Stefano, Fiore Donatella, Fiorino Gionata, Galluzzo Marco, Laterza Lucrezia, Lopetuso Loris, Mensurati Marzia, Monteleone Giovanni, Natalello Gerlando, Ortolan Augusta, Pagnanelli Gianluca, Pani Marcello, Papa Alfredo, Pellacani Giovanni, Persechino Severino, Pica Roberta, Potenza Concetta, Pugliese Daniela, Refolo Pietro, Richetta Antonio, Rumi Filippo, Sacchini Dario, Giacomelli Roberto, Sebastiani Giandomenico, Spagnolo Antonio Gioacchino, Talamonti Marina, Zampaletta Costantino, Petrangolini Teresa, Peris Ketty, D'Agostino Maria Antonietta, Gasbarrini Antonio
Аннотация
METHODS: Three-phases: (1) targeted literature review; (2) round-table discussions involving clinicians, pharmacists, administrators, and patient-representatives, then a modified Delphi survey with iterative voting and refinement; (3) final discussion and approval (consensus: ≥80% agreement on a 5-point Likert-scale).
RESULTS: After three Delphi-rounds, 31 of 37 preliminary statements achieved consensus. Recommendations addressed: cross-stakeholder responsibilities within a regional system; sustainability indicators (biosimilar uptake, persistence, hospitalization rates, PROs/PREMs, direct and indirect costs); criteria for innovation and timely drug availability; and multidisciplinary management for complex IMID patients. Emphasis was placed on biosimilar adoption in biologic-naïve patients, harmonized data collection, and mitigating regional inequalities in access to therapies, key issues in the decentralized Italian SSN.
CONCLUSIONS: This consensus provides a pragmatic multidisciplinary framework to guide sustainable, innovative ADT use in IMIDs, supporting equitable access, optimized resource allocation, and long-term healthcare sustainability within regionalized health systems.